Drugs / ALTO-100
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06656416 | Oct 2024 → Aug 2026 overdue | bipolar depression | Alto Neuroscience | Recruiting | No outcome recorded |
| Phase 2 | NCT05712187 | Jan 2023 → Sep 2024 | major depressive disorder | Alto Neuroscience | Completed | No outcome recorded |
| Phase 2 | NCT05419869 | Jun 2022 → Jan 2023 | major depressive disorder | Alto Neuroscience | Completed | No outcome recorded |
| Phase 2 | NCT05117632 | Dec 2021 → Dec 2022 | major depressive disorder, post-traumatic stress disorder | Alto Neuroscience | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTO-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05117632 ↗ |
| Route | Oral | “ALTO-100 PO tablet” NCT05117632 ↗ |